ClinicalTrials.gg
Active, not recruitingNCT06959316PRAM-T1DUpdated Aug 19, 2026

T1D Pregnancy & Me

An observational study in Diabetes Mellitus, Type 1, Pregnancy in Diabetics and Pregnancy, High-Risk, sponsored by Jaeb Center for Health Research. Active, not recruiting at 10 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Jaeb Center for Health Research · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.

Started
2025
with 1 other
Observational
7 of 36
none open now
Registered
36th of 36
by date

Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 36th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, or all of them as a file.
02

Study summary

T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.

Read the detailed description

Type 1 diabetes (T1D) management during pregnancy is a critical area as pregnancy complicated by T1D is still associated with a markedly elevated risk of maternal and fetal complications. Because the risk of these complications is tightly linked to glucose levels, guidelines recommend lower glycemic targets than in non-pregnant individuals to optimize pregnancy outcomes. Hybrid closed loop (HCL) insulin delivery systems may aid in glycemic management during pregnancy, but options for use of HCL during pregnancy are limited and present challenges as systems are not approved for use in pregnancy and do not target pregnancy glycemic goals. Thus, pregnant individuals with T1D and their clinicians must consider off-label use of HCL systems with suboptimal glycemic targets. To get closer to pregnancy glycemic targets, individuals may adjust the way they use the system, but there is insufficient evidence to understand the impact of HCL systems available in the US on pregnancy glycemic metrics and pregnancy outcomes.

To address these gaps in evidence, we propose an observational study that will enable systematic assessment of HCL system use in pregnancies complicated by T1D. The focus of this study is to assess glycemic outcomes measured by continuous glucose monitors and clinical pregnancy outcomes associated with use of HCL versus other insulin delivery methods. Data collected from this study will provide important information about how individuals in the United States are managing their diabetes during pregnancy and will help us to identify factors that could minimize the risk of diabetes-associated pregnancy complications and reduce the burden that comes with managing T1D in pregnancy.

Pregnant individuals throughout the United States will be enrolled in this remote observational study. Participants will be asked to share details about their diabetes and pregnancy. Participants will also be asked to share diabetes device data from their continuous glucose monitor (CGM). Participants who use an insulin pump or connected insulin pen may also be asked to share these data.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Pregnancy in Diabetics
  • Pregnancy, High-Risk
  • Insulin Dependent Diabetes

Keywords

  • Type 1 diabetes
  • Pregnant
  • Pregnancy
  • Insulin pump
  • Continuous glucose monitor
  • Remote study
  • Online study
  • T1D
  • CGM
  • Insulin injection
  • Hybrid closed loop
  • HCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant adults with type 1 diabetes from across the United States who use a continuous glucose monitor.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Clinical diagnosis of presumed T1D for at least 6 months duration
  3. Less than 15 weeks gestation at time of enrollment based on due date from provider
  4. Planned CGM use on a regular basis (e.g., ≥10 out of 14 days) and willing to continue using CGM regularly with no plans to discontinue CGM use during the study
  5. Following intensive insulin therapy regimen defined as basal-bolus delivery via an insulin pump (including a closed loop system) or multiple daily injections (MDI)
  6. Have access to technology that may be required to complete study questionnaires and share diabetes device data.
  7. Resident of the United States and plans to reside in the U.S. for the duration of the study
  8. Comprehends written and spoken English or Spanish
  9. Willing and able to provide , complete surveys and provide the device data that are part of the protocol

Exclusion criteria

Exclusion Criteria:

  1. Multiple pregnancy
  2. Current renal dialysis or plan to begin renal dialysis during the study
  3. History of liver cirrhosis
  4. Active cancer treatment with systemic chemotherapy
  5. Current participation in other studies involving an insulin delivery device or planning to participate in an investigational insulin delivery device study during pregnancy
  6. Prior participation in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • HCL Use

    Pregnant individuals with type 1 diabetes (T1D) using HCL systems for glycemic management in pregnancy

    Device: Hybrid closed loop insulin delivery system

  • HCL Non-Use

    Pregnant individuals with type 1 diabetes (T1D) not using HCL systems for glycemic management in pregnancy

Interventions

  • DeviceHybrid closed loop insulin delivery system

    Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.

06

What researchers measure

Primary outcomes

  1. CGM Outcome (BG 63-140 mg/dl)

    Percentage of time spent with glucose 63-140 mg/dl

    Time frame: Up to 37 weeks gestation

Secondary outcomes

  1. CGM Outcome (BG<63 mg/dl)

    Percentage time spent with glucose \<63 mg/dl

    Time frame: Up to 37 weeks gestation

  2. CGM Outcome (BG<54 mg/dl)

    Percentage time spent with glucose \<54 mg/dl

    Time frame: Up to 37 weeks gestation

  3. CGM Outcome (BG>140 mg/dl)

    Percentage time spent with glucose \>140 mg/dl

    Time frame: Up to 37 weeks gestation

Other outcomes

  1. Hypertensive disorder of pregnancy

    Gestational hypertension or preeclampsia

    Time frame: Up to 37 weeks gestation

  2. LGA Status (defined as birthweight percentile > 90th)

    Large gestational age birthweight

    Time frame: At birth

  3. Preterm delivery

    Preterm delivery

    Time frame: Delivery after 20 weeks and before 37 weeks gestation

  4. Neonatal Morbidity

    Hypoglycemia, hyperbilirubinemia, respiratory distress, or birth trauma

    Time frame: At birth

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 24 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06959316
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Apr 25, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Robin Gal, MSPH
principal investigator · Jaeb Center for Health Research
Camille Powe, MD
study chair · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion